Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial

Fig. 1

Humoral and T-cell immunity against rAAV2/8-hCYP4V2. a Serum-neutralizing antibodies against AAV8 before and after treatment. The Y-axis represents the 50% fluorescence inhibition rate at a dilution of 1:1000. The 5 participants with the highest neutralizing antibodies at baseline were R011, R012, R010, R004, and R009. b Serum anti-CYP4V2 antibody levels before and after treatment. The Y-axis represents the ratio of CYP4V2 antigen values detected using enzyme-linked immunosorbent assay (ELISA) to the negative control. c T-cell response to AAV8 before and after treatment. The Y-axis represents the ratio of AAV8 SFC detected using Elispot to that of the NC. d T-cell response to CYP4V2 before and after treatment. The Y-axis represents the ratio of CYP4V2 SFC detected using Elispot to that of the NC. The dotted line in the graph represents the positive cut-off value, with values greater than the cut-off value indicating a positive result. SFC spot-forming unit, NC negative control

Back to article page